Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer (KHAD)
This study has been completed.
Study NCT00673127 Information provided by Dana-Farber Cancer Institute
First Received on May 5, 2008. Last Updated on December 27, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Ketaconazole
Hydrocortisone
Dutasteride
Additional drug interventions recognized in this trial
Cortisol succinate
Hormones
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone-17-butyrate
Ketoconazole
More general drug interventions related to this trial
14-alpha Demethylase Inhibitors
5-alpha Reductase Inhibitors
Anti-Infective Agents
Anti-Inflammatory Agents
Antifungal Agents
Dermatologic Agents
Enzyme Inhibitors
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Dana-Farber Cancer Institute
Sunnybrook Health Sciences Centre
Oregon Health and Science University
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center
Back to top of Main Content
